Skip to content

13F-HR filed by Stonepine Capital Management, LLC

Stonepine Capital Management, LLC filed this 13F-HR for the quarter ended 2021-09-30, filed 2021-11-12, with 31 holding rows worth $219,763,000.

Accession
0001567619-21-020046
Filed
2021-11-12
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2021

A holdings report, 31 entries on the cover page, a total value of $219,763,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $219,763,000 with VALUE read as thousands by filing date, 13F file number 028-17175. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
AMRYT PHARMA LTD - SPNR ADR03217L106COMMON EQUITY5,801,748$69,882,000thousands by filing date
CTI BIOPHARMA CORP12648L601COM7,964,329$23,495,000thousands by filing date
ADAMAS PHARMACEUTICALS INC00548A106COM3,914,938$19,222,000thousands by filing date
LAKEFRONT BIOTHERAPEUTICS NV36315X101SPON ADR244,205$12,848,000thousands by filing date
OVID THERAPEUTICS INC690469101COMMON STOCK3,252,892$10,930,000thousands by filing date
CATALYST BIOSCIENCES INC14888D208COM2,635,014$10,830,000thousands by filing date
STRONGBRIDGE BIOPHARMA PLCG85347105SHS USD4,489,687$9,159,000thousands by filing date
APOLLO ENDOSURGERY INC03767D108COM912,125$8,264,000thousands by filing date
AFFIMED N VN01045108COM1,161,466$7,178,000thousands by filing date
GAMIDA CELL LTDM47364100SHS1,724,201$6,759,000thousands by filing date
EXAGEN INC30068X103COM390,637$5,313,000thousands by filing date
CELCUITY INC15102K100COM294,692$5,304,000thousands by filing date
YUMANITY THERAPEUTICS INC98872L102COM481,692$4,971,000thousands by filing date
ATYR PHARMA INC002120202COM NEW410,535$3,728,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM200,000$3,490,000thousands by filing date
SYNLOGIC INC87166L100COM1,000,000$3,050,000thousands by filing date
ANGION BIOMEDICA CORP03476J107COM280,183$2,737,000thousands by filing date
EVOLUS INC30052C107COM300,000$2,286,000thousands by filing date
AVALO THERAPEUTICS INC05338F108CMN850,000$1,853,000thousands by filing date
CIDARA THERAPEUTICS INC COM NEW171757107Stock782,817$1,754,000thousands by filing date
XOMA ROYALTY CORPORATION98419J206COMMON STOCK68,542$1,696,000thousands by filing date
LEAP THERAPEUTICS INC52187K101COM250,000$1,003,000thousands by filing date
ANTARES PHARMA INC036642106COM264,100$961,000thousands by filing date
EYEPOINT INC COM NEW30233G209Stock80,537$839,000thousands by filing date
DIAMEDICA THERAPEUTICS INC25253X207COMMON STOCK165,775$665,000thousands by filing date
CONFORMIS INC20717E101COM486,982$648,000thousands by filing date
Ohr Pharmaceutical Inc64132K102COM109,742$396,000thousands by filing date
IMMUNIC INC4525EP101COM22,409$198,000thousands by filing date
CONTRAFECT CORP212326300COM34,413$139,000thousands by filing date
SEASPINE HLDGS CORP81255T108COM8,349$131,000thousands by filing date
SCYNEXIS INC811292200COM NEW6,327$34,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001567619-21-020046this filing2021-11-12acceptance time not in the bulk data set